Exscientia achieves molecule discovery milestone as part of GSK collaboration

Oxford, UK, 3rd April 2019: Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company – announces today that it has delivered a highly potent in vivo active lead molecule, targeting a novel pathway for the treatment of chronic obstructive pulmonary disease (COPD). By delivering the candidate, it has reached the first major milestone in its AI-drug discovery collaboration with GSK.

  • First selective and potent in vivo active lead molecule to be delivered under Exscientia’s AI collaboration with GlaxoSmithKline (GSK), targeting a key pathway for the treatment of chronic obstructive pulmonary disease (COPD).

  • In vivo active lead milestone discovered with 5 cycles and only 85 compounds tested.

Exscientiaがアジアの創薬マーケットを狙った子会社を日本に設立

Exscientia社(エクセンシア)は、人工知能(AI)創薬で世界最先端を行く企業ですが、この度日本に子会社Exscientia株式会社を設立し、アジアにおけるビジネスを強化します。Exscientia株式会社は本社を大阪市に置き、田中大輔博士が責任者となります。

Exscientia continues expansion with establishment of a subsidiary in Japan to target the pharmaceutical market across Asia

Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company announces the establishment of a subsidiary, Exscientia K.K to spearhead  its pharmaceutical interests across Asia.

Exscientia K.K. is headquartered in Osaka, Japan, and led by Dr Daisuke Tanaka, an experienced medicinal chemist who previously was Director of the Innovative Chemistry Group at Sumitomo Dainippon Pharma (DSP).

Celgene and Exscientia enter 3-year AI drug discovery collaboration focused on accelerating drug discovery in oncology and autoimmunity

Oxford, UK, 21 March 2019: Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $25 million upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program. In addition, Exscientia is due to receive tiered royalties on net sales on any product resulting from the collaboration. Exscientia will apply its full-stack AI drug discovery capabilities to the execution of the entire project – from gene to the drug candidate.

Exscientia hires Director of Data Engineering to scale up its AI drug discovery platform

Following a highly successful year and several drug discovery milestones using its flagship AI platform, Exscientia are pleased to welcome Andrew Douglas as the new Director of Data Engineering.

Andrew joins Exscientia from Winton Capital, a global investment management and data science company, where he led the design and creation of platforms, algorithms and models to automate data processing, analyse data and predict outcomes

Exscientia Raises US$26 Million in Series B Financing Round to Accelerate Scaling as the Leading AI Drug Discovery Company

NEW INVESTORS CELGENE CORPORATION AND GT HEALTHCARE CAPITAL PARTNERS JOIN SERIES A INVESTOR EVOTEC.

Exscientia – the world-leading Artificial Intelligence (AI)-driven drug discovery company – today announces it has raised US$26 million in a Series B financing round. This will be used to scale the company’s pipeline and advance selected programmes towards clinical development. The round included participation from new investors Celgene Corporation and specialist healthcare investor GT Healthcare Capital Partners, as well as existing investor Evotec AG.

Exscientia Initiates Sixth AI Drug Discovery Partnership

EXSCIENTIA TO RECEIVE UP TO CHF 67 MILLION IN UPFRONT PAYMENTS, RESEARCH SUPPORT AND MILESTONE PAYMENTS IN DISCOVERY COLLABORATION WITH ROCHE

Exscientia – the world-leading Artificial Intelligence (AI)-driven drug discovery company - is pleased to announce a drug discovery collaboration with Roche. 

Exscientia will apply its cutting-edge, Centaur Chemist™, AI drug discovery platform to design pre-clinical drug candidates for Roche. Roche has the exclusive rights to develop and market the drug candidates resulting from the collaboration.

Exscientia receives upfront and research funding as well as pre-clinical, development and commercial milestone payments. Together, the combined financial reward is worth up to CHF 67 million to Exscientia, plus tiered royalties on the annual net sales of any products resulting from the collaboration.

Exscientia Builds “Full Stack” AI-driven Drug Discovery Capabilities through Acquisition of Kinetic Discovery

Exscientia Builds “Full Stack” AI-driven Drug Discovery Capabilities through Acquisition of Kinetic Discovery

Exscientia, the company leading the use of Artificial Intelligence (AI) in drug discovery, announces that is has acquired the biophysics specialists, Kinetic Discovery, a private UK company. The acquisition builds up Exscientia’s capabilities for the tackling novel drug targets to create first-in-class drug candidates by seeding its algorithms with data generated through the use of fragment screening and structural biology. The addition of Kinetic’s complementary expertise enables Exscientia to create a “full stack” AI-driven drug discovery company to go rapidly from gene to clinical candidate for any druggable target of choice. The acquisition of Kinetic is part of Exscientia’s growth strategy to develop a proprietary drug pipeline and to enhance its support of existing and future partnerships.